| Wöhrle, Jochen |
NCT05114850: Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve® |
|
|
| Recruiting | N/A | 450 | Europe | | P+F Products + Features GmbH | Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Insufficiency, Heart Failure, Heart Diseases, Heart Valve Diseases | 12/25 | 12/28 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Burchardt, Alexander |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
| Sinning, Jan-Malte |
AHEAD, NCT03339115: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System |
|
|
| Recruiting | N/A | 30 | Europe | Cardiovalve Transfemoral Mitral Valve | Cardiovalve Ltd., Meditrial Europe Ltd., Meditrial SrL | Mitral Regurgitation, Mitral Valve Disease | 12/24 | 12/29 | | |
NCT06181240: Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) |
|
|
| Recruiting | N/A | 400 | Europe | Intravascular lithotripsy | Bolt Medical | Coronary Artery Disease, Coronary Artery Calcification | 04/25 | 03/26 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Böning, Andreas |
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery |
|
|
| Terminated | 2 | 177 | Europe, Canada, US, RoW | RMC-035, ROSgard, Placebo | Guard Therapeutics AB | Acute Kidney Injury | 04/23 | 07/23 | | |
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery |
|
|
| Recruiting | 2 | 161 | Europe, Canada | RMC-035, Placebo | Guard Therapeutics AB | Kidney Injury Following Open-Chest Cardiac Surgery | 10/25 | 10/25 | | |
| Nef, Holger |
TriCLASP, NCT04614402: Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System |
|
|
| Active, not recruiting | N/A | 300 | Europe | Edwards PASCAL Transcatheter Valve Repair System, Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Tricuspid Valve Insufficiency | 04/23 | 03/28 | | |
| Recruiting | N/A | 500 | Europe | IASD Implant | Corvia Medical | Heart Failure | 07/26 | 07/28 | | |
NCT06181240: Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) |
|
|
| Recruiting | N/A | 400 | Europe | Intravascular lithotripsy | Bolt Medical | Coronary Artery Disease, Coronary Artery Calcification | 04/25 | 03/26 | | |
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System |
|
|
| Active, not recruiting | N/A | 400 | Europe | Reducer System, Reducer | Neovasc Inc., Shockwave Medical, Inc. | Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina | 11/23 | 12/28 | | |
| Recruiting | N/A | 1000 | Europe | Edwards PASCAL Transcatheter Valve Repair System and Edwards PASCAL Precision Transcatheter Valve Repair System | Edwards Lifesciences | Mitral Regurgitation, Mitral Insufficiency | 12/25 | 03/31 | | |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Nordbeck, Peter |
| Terminated | 3 | 17 | Europe, Canada | REPLAGAL, SHP675 | Shire | Fabry Disease | 12/22 | 12/22 | | |
| Active, not recruiting | 1/2 | 34 | Europe, Canada, US, RoW | ST-920 | Sangamo Therapeutics | Fabry Disease | 04/25 | 09/25 | | |
NCT03022851: The Prophet Trial -Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension |
|
|
| Recruiting | N/A | 30 | Europe, RoW | Occlutech AFR Device | Occlutech International AB | Pulmonary Hypertension | 02/23 | 12/23 | | |
| Recruiting | N/A | 750 | Europe, Canada, US, RoW | Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) | Corvia Medical | Heart Failure, Heart Failure, Diastolic | 05/25 | 03/31 | | |
| Active, not recruiting | N/A | 965 | Europe, US | ommitence of defibrillation testing | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation | Ventricular Arrythmia | 04/25 | 07/25 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Gall, Henning |
| Completed | 2 | 108 | Europe, Canada, US, RoW | rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo | Altavant Sciences GmbH | Pulmonary Arterial Hypertension | 06/23 | 08/23 | | |
| Wehler, Thomas |
NCT04413201: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC |
|
|
| Active, not recruiting | 4 | 34 | Europe | Afatinib, Osimertinib | Michael Hopp, Boehringer Ingelheim | Non-squamous NSCLC | 06/24 | 06/24 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
| Recruiting | 2 | 105 | Europe | Durvalumab, IMFINZI®, standard of care | Michael Hopp, AstraZeneca | Small Cell Lung Cancer Limited Stage | 09/23 | 09/23 | | |
| Active, not recruiting | 2 | 36 | Europe | Copanlisib, Aliqopa, Rituximab, Truxima | Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer | Marginal Zone Lymphoma | 06/24 | 12/29 | | |
| Completed | 2 | 92 | Europe | Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg | Pleural Mesothelioma Malignant | 01/25 | 01/25 | | |
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy |
|
|
| Not yet recruiting | 2 | 126 | Europe | bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich | Metastatic Gastro-esophageal Adenocarcinoma | 09/27 | 03/28 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
| Samra, Maisun Abu |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
| Schroers, Roland |
| Recruiting | 4 | 50 | Europe | Upfront autologous HSCT | UMC Utrecht, ZonMw: The Netherlands Organisation for Health Research and Development, Boehringer Ingelheim, Miltenyi Biotec, Inc. | Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma, Scleroderma, Diffuse, Autologous Stem Cell Transplantation, Cyclophosphamide, Mycophenolate Mofetil, Treatment Strategy | 10/27 | 10/30 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 10/25 | 06/33 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
| Eul, Bastian |
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping |
|
|
| Active, not recruiting | 2 | 118 | Europe | Brigatinib, Study treatment, Tyrosine kinase inhibitor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda | NSCLC | 01/26 | 01/26 | | |
NCT05882734: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) |
|
|
| Active, not recruiting | 1/2 | 61 | Europe, Japan, US, RoW | M1774, Tuvusertib, Cemiplimab | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-Small Cell Lung Cancer | 05/25 | 02/26 | | |
| Kalder, Johannes |
| Active, not recruiting | N/A | 260 | Europe, Canada, US, RoW | JETi Peripheral Thrombectomy System | Abbott Medical Devices | Peripheral Artery Thrombosis, Peripheral Venous Thrombosis | 08/24 | 08/25 | | |
NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers |
|
|
| Recruiting | N/A | 178 | Europe, US | Biatain Ag, Cutimed Siltec Sorbact | Coloplast A/S | Wound Heal | 10/25 | 10/25 | | |
| Landt, Martin |
| No trials found |
